Displaying drugs 2126 - 2150 of 2320 in total
Topsalysin
Topsalysin is being developed for the treatment of localized prostate cancer and also benign prostatic hyperplasia. Topsalysin is delivered locally to the prostate under ultrasound guidance.
Investigational
Interferon Kappa
Interferon kappa is a subclass of type I interferon mediating host defence which consists of 207 amino acids and has 30% homology with others of the same class as it consists of a series of cysteine and a 27-amino acid signal peptide conserved in type I interferons. This gene encoding...
Investigational
Matched Description: … a 27-amino acid signal peptide conserved in type I interferons. ... Interferon kappa is a subclass of type I interferon mediating host defence which consists of 207 amino ... acids and has 30% homology with others of the same class as it consists of a series of cysteine and …
Zagotenemab
Zagotenemab is under investigation in clinical trial NCT03518073 (A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease).
Investigational
Matched Description: … Zagotenemab is under investigation in clinical trial NCT03518073 (A Study of LY3303560 in Participants …
BRG01
BRG01 is a genetically modified autologous CAR-T cell therapy under investigation for the treatment of nasopharyngeal carcinoma.
Investigational
Matched Description: … BRG01 is a genetically modified autologous CAR-T cell therapy under investigation for the treatment of …
MRT5005
MRT5005 is a human cystic fibrosis transmembrane conductance regulator (hCFTR) messenger RNA (mRNA) complexed with branched polyethyleneimine (bPEI).
Investigational
Matched Description: … MRT5005 is a human cystic fibrosis transmembrane conductance regulator (hCFTR) messenger RNA (mRNA) complexed …
SLN500
SLN500 is a synthetic double-strand small interfering ribonucleic acid (siRNA) oligonucleotide drug directed against C3 messenger RNA
Investigational
Matched Description: … SLN500 is a synthetic double-strand small interfering ribonucleic acid (siRNA) oligonucleotide drug directed …
CTCE-0214
CTCE-0214 is a stable peptide agonist of stromal cell-derived factor-1 (SDF-1), a key signaling molecule in the proliferation, homing, engraftment and expansion of hematopoietic stem cells and white blood cells.
Investigational
Matched Description: … CTCE-0214 is a stable peptide agonist of stromal cell-derived factor-1 (SDF-1), a key signaling molecule …
Zofin
Zofin, previously known as Organicell Flow, is a nanoparticle-based therapeutic derived from perinatal sources which is manufactured in a way that retains the naturally occurring microRNAs without the addition of other substances .
Investigational
Matched Description: … Zofin, previously known as Organicell Flow, is a nanoparticle-based therapeutic derived from perinatal ... sources which is manufactured in a way that retains the naturally occurring microRNAs without the addition …
Depatuxizumab mafodotin
Depatuxizumab/Denintuzumab mafodotin has been used in trials studying the treatment of Lymphoma, Gliosarcoma, Glioblastoma, Malignant Glioma, Squamous Cell Tumors, and Glioblastoma Multiforme.
Investigational
Meplazumab
Meplazumab is a humanized anti-CD147 antibody being investigated as an add-on therapy in patients with COVID-19 pneumonia.
Investigational
Matched Description: … Meplazumab is a humanized anti-CD147 antibody being investigated as an add-on therapy in patients with …
CSIC002
CSIC002 is a small-molecule Sema-3A inhibitor. It is being investigated for the treatment of anterior ischemic optic neuropathy.
Investigational
Matched Description: … CSIC002 is a small-molecule Sema-3A inhibitor. …
FCR001
FCR001 is a somatic cell therapy product containing hematopoietic progenitor cells (HPC), Facilitating Cells (FC), and alpha beta T cells.
Investigational
Matched Description: … FCR001 is a somatic cell therapy product containing hematopoietic progenitor cells (HPC), Facilitating …
Navicixizumab
Navicixizumab is under investigation in clinical trial NCT02298387 (A Phase 1 Study of Navicixizumab in Subjects With Solid Tumors).
Investigational
Matched Description: … Navicixizumab is under investigation in clinical trial NCT02298387 (A Phase 1 Study of Navicixizumab …
Pegapamodutide
Pegapamodutide is under investigation in clinical trial NCT02188303 (A Study of LY2944876 in Healthy Japanese and Non-Japanese Participants).
Investigational
Matched Description: … Pegapamodutide is under investigation in clinical trial NCT02188303 (A Study of LY2944876 in Healthy …
E59
E59 is a humanized IgG1 low affinity allergic reactivity inhibiting (LARI) monoclonal antibody. It was developed by Sixal Inc.
Investigational
Matched Description: … E59 is a humanized IgG1 low affinity allergic reactivity inhibiting (LARI) monoclonal antibody. …
SIG-001
SIG-001 is a cultured human retinal pigment epithelial cell line (ARPE-19) genetically modified with a non-viral vector to express B domain deleted human factor VIII protein, encapsulated within two-layer modified alginate spheres.
Investigational
Matched Description: … SIG-001 is a cultured human retinal pigment epithelial cell line (ARPE-19) genetically modified with ... a non-viral vector to express B domain deleted human factor VIII protein, encapsulated within two-layer …
Shea butter
Shea butter is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Experimental
Matched Description: … Shea butter is a plant/plant extract used in some OTC (over-the-counter) products. …
Tangerine peel
Tangerine peel is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Experimental
Matched Description: … Tangerine peel is a plant/plant extract used in some OTC (over-the-counter) products. …
Macadamia oil
Macadamia oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Experimental
Matched Description: … Macadamia oil is a plant/plant extract used in some OTC (over-the-counter) products. …
Oleclumab
Oleclumab is under investigation in clinical trial NCT03819465 (A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC).
Investigational
Matched Description: … Oleclumab is under investigation in clinical trial NCT03819465 (A Study of Novel Anti-cancer Agents in …
OTOF-GT
OTOF-GT is a dual vector AAV gene therapy being investigated for the restoration of hearing loss associated with otoferlin deficiency.
Investigational
Matched Description: … OTOF-GT is a dual vector AAV gene therapy being investigated for the restoration of hearing loss associated …
XL019
XL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. An IND for XL019 was filed by Exelixis in May 2007.
Investigational
Matched Description: … XL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. …
DCVax-L
DCVax-L is a personalized immunotherapy comprising an autologous vaccine with dendritic cells loaded in vitro with autologous tumour lysate.
Investigational
Matched Description: … DCVax-L is a personalized immunotherapy comprising an autologous vaccine with dendritic cells loaded …
Orgotein
Superoxide is a natural byproduct of oxygen metabolism which, if left unchecked, leads to cell damage. Superoxide dismutase (SOD) is an enzyme that alternately catalyzes the dismutation of the superoxide radical into either the less damaging hydrogen peroxide or molecular oxygen. Hydrogen peroxide can be degraded by catalase. The antioxidant...
Investigational
Vet approved
Matched Description: … A notable exception is Lactobacillus plantarum. ... Superoxide is a natural byproduct of oxygen metabolism which, if left unchecked, leads to cell damage …
Displaying drugs 2126 - 2150 of 2320 in total